论文部分内容阅读
LCZ-696是诺华公司开发、由血管紧张素受体阻滞剂缬沙坦和脑啡肽酶阻断剂sacubitril组成的抗心衰复方新药,因具有对血管紧张素受体-脑啡肽酶的双重抑制作用,在临床试验中其对心衰患者展现出卓越疗效,尤其在改善生存率方面更是凸显优势。介绍LCZ-696的临床开发和主要疗效以及后期开发计划、市场前景展望、面临的挑战等。
LCZ-696 is Novartis company developed by the angiotensin receptor blocker valsartan and neprilysin blockers sacubitril composition of new anti-heart failure medicine, because of angiotensin receptor - neprilysin The dual inhibition in clinical trials in patients with heart failure showed excellent efficacy, especially in improving the survival rate is even more prominent advantage. Introduce the clinical development and main efficacy of LCZ-696 as well as the development plan of the later stage, market prospect, challenges and so on.